BSX Q3 2021 Earnings — Boston Scientific Corporation Revenue & Financial Results | Market Cap Arena

BSXBoston Scientific Corporation

$103B

Q3 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$2.9B+10.3% YoY

Gross Profit

$1.8B62.5% margin

Operating Income

$442M15.1% margin

Net Income

$419M14.3% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

-4.7%

Cash Flow

Operating Cash Flow

$465M

Free Cash Flow

$358M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$31.9B

Total Liabilities

$15.4B

Stockholders' Equity

$16.5B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.9B	$2.7B	+10.3%
Gross Profit	$1.8B	$1.6B	+16.5%
Operating Income	$442M	$262M	+68.7%
Net Income	$419M	-$155M	+370.3%

Revenue Segments

Cardiovascular

$1.2B41%

MedSurg

$917M31%

Cardiac Rhythm Management

$819M28%

Geographic Segments

UNITED STATES

$1.7B59%

Non-US

$1.2B41%